ARTICLE | Clinical News
Menveo: Phase III data
November 1, 2010 7:00 AM UTC
Menveo is approved to prevent invasive meningococcal disease caused by Neisseria meningitides serogroups A, C, W135 and Y in subjects ages 11-55 in the U.S., Chile and Argentina, and in subjects >=11 ...